Zevra Therapeutics to Participate at Upcoming Investor Conferences

KMPH 11.26.2024

Full Press ReleaseSEC FilingsOur KMPH Tweets

About Gravity Analytica

Recent News

  • 12.17.2024 - Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024
  • 12.06.2024 - Zevra Therapeutics Announces Organizational Changes
  • 12.04.2024 - Piper Sandler 36th Annual Healthcare Conference

Recent Filings

  • 12.06.2024 - EX-99.1 EX-99.1
  • 12.06.2024 - 8-K Current report

CELEBRATION, Fla.,Nov. 26, 2024(GLOBE NEWSWIRE) --Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced thatNeil F. McFarlane, President and Chief Executive Office of Zevra, will participate in the following December investor events.

  • Piper Sandler 36thAnnual Healthcare Conference, onWednesday, December 4, 2024, at10:30 a.m. ET.

  • Oppenheimer Movers in Rare Disease Summit Elevator Pitches from Rare Disease Companies withKey Near-term, Potentially Stock-moving Catalysts, onThursday, December 12, 2024, at2:45 p.m. ETas part of an invitation-only event hosted by Oppenheimer.

Additionally, management will be available for one-on-one meetings with registered attendees at each conference. The live webcast of the Piper Sandler fireside chat will be accessible via “Events & Presentations” on the Investor Relations section of Zevra’s website atinvestors.zevra.com.

AboutZevra Therapeutics, Inc.

Zevra Therapeutics, Inc.is a commercial-stage rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.

For more information, please visitwww.zevra.comor follow us onX(formerly Twitter) andLinkedIn.

Caution Concerning Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra’s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year endedDec. 31, 2023, Zevra’s Quarterly Report for the quarter endedSept. 30, 2024, and Zevra’s other filings with theSecurities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.

Zevra Contact

Nichol Ochsner+1 (732) 754-2545nochsner@zevra.com

Russo Partners Contact

David Schull+1 (858) 717-2310david.schull@russopartnersllc.com

Primary Logo

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com